Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Depemokimab, the first ultra-long-acting anti-IL-5 monoclonal antibody, significantly reduced exacerbation rates in patients with severe eosinophilic asthma when administered biannually. While it offers potential benefits for patient adherence and convenience, the trials showed no improvement in symptoms and lung function. Further research is needed to determine its optimal place in therapy and identify patients who will benefit the most.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.medj.2024.10.022 | DOI Listing |
Publication Analysis
Top Keywords
depemokimab ultra-long-acting
8
ultra-long-acting anti-il-5
8
anti-il-5 monoclonal
8
monoclonal antibody
8
severe eosinophilic
8
eosinophilic asthma
8
antibody severe
4
asthma depemokimab
4
antibody reduced
4
reduced exacerbation
4